Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MERTK | Q12866 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22440005 | 0.80 | LMNA (0.63) | LMNAKDM4EALDH1A1HPGDMAPK14 | |
| SCHEMBL2946003 | 0.77 | MAPK14 (0.49) | LMNAKDM4EHTTALDH1A1HPGD | |
| SCHEMBL2954373 | 0.77 | MAPK14 (0.49) | LMNAKDM4EALDH1A1MAPK14MAPK1 | |
| SCHEMBL600413 | 0.74 | GRM4 (0.45) | LMNAHTTALDH1A1MAPK14MAPK1 | |
| SCHEMBL30493094 | 0.71 | MAPK14 (0.47) | LMNAKDM4EHTTALDH1A1HPGD | |
| SCHEMBL30855000 | 0.70 | KDM1A (0.65) | LMNAKDM4EHTTALDH1A1HPGD | |
| SCHEMBL1825303 | 0.70 | LMNA (0.97) | LMNAKDM4EHTTALDH1A1HPGD | |
| SCHEMBL2944698 | 0.70 | MAPK14 (0.50) | LMNAKDM4EALDH1A1HPGDMAPK14 | |
| SCHEMBL22911985 | 0.68 | KMT2A (0.40) | LMNAALDH1A1HPGDMAPK14MAPK1 | |
| SCHEMBL2948699 | 0.68 | MAPK14 (0.59) | ALDH1A1MAPK14MAPK1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497269-B2 | Phthalazine compounds as p38 map kinase modulators and methods of use thereof | AMGEN INC. (US) | 2013-07-30 | — | — | US | claimed |
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2012-02-16 | — | — | US | claimed |
| WO-2010042649-A2 | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-04-15 | — | — | WO | claimed |
| US-8497269-B2 | Phthalazine compounds as p38 map kinase modulators and methods of use thereof | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010042649-A2 | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | MAPK1, MAPK4, MAPK12 | LMNA 4011/4885KDM4E 3000/4885HTT 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.